

**Investigation of the pathogenic agent in a *Drosophila*
model of polyglutamine disease**

A thesis submitted for the degree of Doctor of Philosophy, March 2006

Catherine McLeod, B. Sc. (Biomed.) (Hons.)

School of Molecular and Biomedical Sciences, Discipline of Genetics
Centre for the Molecular Genetics of Development,
Adelaide University

Table of Contents

Index of Figures and Tables.....	V
Declaration.....	VII
Acknowledgements.....	IX
Abstract.....	XI
Chapter 1 – Background Literature.....	1
Repeat Expansion Diseases.....	1
Polyglutamine diseases.....	2
Toxicity of expanded polyglutamine.....	7
Mouse models of Polyglutamine Disease.....	7
<i>Drosophila</i> models of polyglutamine disease.....	11
Nuclear Aggregates.....	12
One pathogenic pathway or many?.....	16
Alternative hypothesis: pathogenic polyalanine.....	18
Untranslated repeats.....	20
RNA Pathogenesis.....	24
Animal models of untranslated repeat disorders.....	27
Hypothesis:	
RNA as a unifying pathogenic agent in expanded repeat diseases....	28
Approach: use of the <i>Drosophila</i> eye as a model.....	36
Chapter 2 – Materials and Methods.....	39
Materials.....	39
Methods.....	42
Chapter 3 – Investigation of RNA pathogenesis.....	51
Introduction.....	51
Results.....	52
Discussion.....	65
Chapter 4 – Investigation of alternative pathogenic pathways.....	73
Introduction.....	73
A. DNA damage hypotheses.....	73
B. Axon transport hypothesis.....	80

Results.....	83
Discussion.....	91
Chapter 5 – RNA Pathogenesis Revisited.....	95
Introduction.....	95
Results.....	96
Discussion.....	113
Chapter 6 – Discussion.....	119
Summary of Results.....	119
Implications for polyglutamine pathogenesis.....	120
Is <i>Drosophila</i> an appropriate model for polyglutamine disease?.....	122
A <i>Drosophila</i> model of RNA-mediated neurodegeneration.....	124
Future Experiments.....	125
References.....	128

Index of Figures and Tables

Table 1.1	Polyglutamine diseases described to date.....	2
Table 1.2	Diseases caused by expansion of untranslated triplet repeats..	21
Figure 1.1	Pathogenic thresholds for the untranslated repeat diseases roughly overlap the pathogenic threshold for the polyglutamine diseases.....	31
Figure 1.2	Appearance and structure of the <i>Drosophila</i> eye.....	38
Figure 1.3	Effect of polyglutamine peptide expression in the <i>Drosophila</i> eye	39
Figure 3.1	Schematic representation of repeat constructs.....	53
Figure 3.2	Secondary structure predictions for CAG and CAA repeats.....	55
Figure 3.3	Effect of expressing various repeat constructs on the external appearance of the <i>Drosophila</i> eye.....	56
Figure 3.4	Effect of expressing expanded repeats in the <i>Drosophila</i> eye driven by <i>GMR-GAL4</i> varies between lines.....	57
Figure 3.5	Expression of (CAG) ₅₂ in the <i>Drosophila</i> eye causes loss of pigment and photoreceptor neurons.....	58
Figure 3.6	Distribution of polyglutamine proteins in the <i>Drosophila</i> eye.....	59
Figure 3.7	Expression levels of translated and untranslated CAG repeat transcripts.....	61
Figure 3.8	Effect of GCA and CTG repeat constructs on the external appearance of the <i>Drosophila</i> eye.....	62
Figure 3.9	The GCA repeat transcript is expressed at similar levels to the translated and untranslated CAG repeat transcripts.....	63
Figure 3.10	Polyalanine proteins cannot be detected by western blot.....	64
Figure 3.11	Polyleucine proteins cannot be detected by western blot...	65
Figure 3.12	Detection of polyalanine and polyleucine proteins in the <i>Drosophila</i> eye.....	67
Table 4.1	Mutations in DNA repair genes tested for modification of the polyglutamine eye phenotype.....	80
Table 4.2	Alleles of axon transport pathway components tested for enhancement of polyglutamine eye phenotype.....	84
Figure 4.1	Mutation of genes involved in DNA repair does not visibly affect the polyglutamine eye phenotype.....	87

Figure 4.2	Mutation of genes involved in DNA repair does not visibly affect a milder polyglutamine eye phenotype.....	89
Figure 4.3	Mutation of genes involved in axon transport does not visibly affect the polyglutamine eye phenotype.....	91
Figure 4.4	Severe and mild polyglutamine eye phenotypes can be modified by manipulation of Hsp70 activity.....	92
Figure 4.5	The polyglutamine eye phenotype is not modified by previously described enhancers of the ataxin-1 phenotype.....	93
Figure 5.1	Schematic representation of repeat constructs.....	96
Figure 5.2	Expression of rCUG in the <i>Drosophila</i> eye causes a rough eye phenotype in two out of 14 lines.....	97
Figure 5.3	Effect of expressing two copies of untranslated repeat transcripts in the <i>Drosophila</i> eye.....	99
Figure 5.4	Effect of expressing RNA repeat transcripts in the <i>Drosophila</i> eye driven by <i>GMR-GAL4</i> varies between lines.....	101
Figure 5.5	Read through products containing an expanded repeat cannot be detected by western blot.....	102
Figure 5.6	Effect of expression of repeat-containing transcripts on the <i>Drosophila</i> eye before and after ageing.....	106
Figure 5.7	Distribution of Hsp70 in the eye of <i>Drosophila</i> expressing translated or untranslated repeat transcripts.....	109
Figure 5.8	Modulation of Hsp70 activity modifies the rCAG and rCUG phenotypes.....	111
Figure 5.9	Expression of the apoptotic inhibitor p35 has a modest effect on the rCAG and rCUG phenotypes.....	112

Declaration

This work contains no material that has been accepted for the award of any other degree or diploma in any university or other tertiary institution and, to the best of my knowledge and belief, contains no material previously published or written by another person, except where due reference has been made in the text.

I give consent to this copy of my thesis, when deposited in the University Library, being available for loan and photocopying.

Catherine McLeod

Acknowledgements

I would like to thank my supervisor, Rob Richards, for all of his great ideas and for giving me independence, as well as the occasional nudge along when I needed it. Thanks also to Louise O'Keefe, second supervisor and fly expert, for helpful discussions and advice. Thanks to Volkan Evci and Jo Milverton for doing the microinjections to generate transgenic flies. Finally, thanks to the members of the Richards lab for providing input, as well as support and a fun place to work.

Abstract

A substantial body of evidence supports the identity of polyglutamine as the pathogenic agent in a variety of human neurodegenerative diseases (some of which are clinically indistinguishable from the polyglutamine diseases) that are due to expanded repeats that cannot encode polyglutamine. As polyglutamine cannot be the pathogenic agent in these diseases, either the different disorders have distinct pathogenic pathways or some other common agent is toxic in all of the expanded repeat diseases. Recently, evidence has been presented in support of RNA as the pathogenic agent in Fragile X- associated tremor/ataxia syndrome (FXTAS), caused by expanded CGG repeats at the *FRAXA* locus. A *Drosophila* model of FXTAS, in which 90 copies of the CGG repeat are expressed in an untranslated region of RNA, exhibits both neurodegeneration and similar molecular pathology to the polyglutamine diseases. Therefore the identity of the pathogenic agent in a *Drosophila* model of the polyglutamine diseases was explored. This included examining the possibility that RNA mediates the disease phenotype by expression of repeat constructs including expanded CAA and CAG repeats and an untranslated CAG repeat. Alternative putative pathogenic mechanisms including polyalanine toxicity, DNA damage and axonal blockage were also examined. The results obtained support the identity of polyglutamine as the pathogenic agent in this *Drosophila* model of polyglutamine disease. However, additional preliminary results were obtained suggesting that repeat-containing RNA expressed at a sufficiently high level can exert a toxic effect. The phenotype induced by repeat-containing RNA in *Drosophila* is milder than the polyglutamine phenotype, characterised by degeneration and shows cell type-specificity. Thus, although in this *Drosophila* model, polyglutamine toxicity appears to occur in the absence of a contribution by RNA, the possibility that it contributes towards pathogenesis in the human diseases cannot be ruled out.